Atamestane

Atamestane
Clinical data
Other names	SH-489; Metandroden; 1-Methylandrosta-1,4-diene-3,17-dione
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	UK: Class C;
Identifiers
	IUPAC name (8R,9S,10S,13S,14S)-1,10,13-Trimethyl-7,8,9,11,12, 14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione;
CAS Number	96301-34-7 ;
PubChem CID	57050;
ChemSpider	51438 ;
UNII	62GA3K28B6;
ChEMBL	ChEMBL2105987 ;
CompTox Dashboard (EPA)	DTXSID30869268 ;
Chemical and physical data
Formula	C20H26O2
Molar mass	298.426 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1/C=C(/C)[C@]4(C(=C/1)/CC[C@@H]3[C@@H]4CC[C@@]2(C(=O)CC[C@H]23)C)C;
	InChI InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1 ; Key:PEPMWUSGRKINHX-TXTPUJOMSA-N ;

Atamestane (developmental code name SH-489), also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer. It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase.